KALA revenueFY2025$0
KALA revenue was $0 for fiscal 2025 (ended Dec 31, 2025), compared with $0 in fiscal 2024.
KALA BIO Inc. (KALA) financials
For fiscal 2025 (ended Dec 31, 2025), KALA BIO Inc. reported $0 of revenue and -$26.98M of net income.
- Revenue, FY2025
- $0
- Net income, FY2025
- -$26.98M
- EPS, diluted, FY2025
- -$165.50
- Cash
- $229.0K
- Market cap
- $3.4M
FY2016FY2025
FY2016FY2025
FY2016FY2019
KALA revenue and earnings growth
KALA net incomeQ2 2026-$1.58M
KALA net income was -$1.58M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$11.15M a year earlier. For the full fiscal 2025 it was -$26.98M, compared with -$38.51M in fiscal 2024.
KALA EPSQ2 2026-$21.32
KALA diluted EPS was -$21.32 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$165.50.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $3.89M | $11.24M | $6.36M | $6.07M | - | $0 | $0 |
| Research and development | $18.78M | $22.09M | $18.59M | $17.65M | $11.52M | $18.35M | $27.27M | $29.29M | $29.01M | $25.03M |
| Selling, general and admin | $23.63M | $18.34M | $20.57M | $65.03M | $105.06M | $81.07M | $65.02M | $35.43M | $10.87M | $7.64M |
| Operating income | -$39.16M | -$40.98M | -$39.66M | -$81.71M | -$130.25M | -$96.23M | -$88.22M | -$64.72M | -$39.88M | -$32.67M |
| Interest expense | $3.28M | $5.78M | $5.81M | $7.27M | $8.38M | $8.59M | $8.48M | $3.31M | $1.02M | $767.0K |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$26.98M | -$38.51M | -$42.20M | -$44.82M | -$142.60M | -$104.33M | -$94.35M | -$66.74M | -$42.21M | -$33.17M |
| EPS, basic | -$165.50 | -$507.50 | -$867.50 | -$1474.00 | -$5416.00 | -$4925.25 | -$6831.00 | -$6162.75 | -$9182.25 | -$69473.25 |
| EPS, diluted | -$165.50 | -$507.50 | -$867.50 | -$1474.00 | -$5416.00 | -$4925.25 | -$6831.00 | -$6162.75 | -$9182.25 | -$69473.25 |
| Diluted shares | 162,965.5 | 75,920.94 | 48,640.16 | 30,412.22 | 26,329.9 | 21,162.637 | 13,822.124 | 10,809.659 | 4,595.96 | 477.345 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.56M | $51.18M | $50.90M | $70.50M | $92.14M | $77.26M | $85.45M | $170.90M | $114.70M | $45.58M |
| Short-term investments | - | - | - | - | - | $76.28M | - | - | - | - |
| Receivables | - | - | - | $195.0K | $15.35M | $9.60M | $11.56M | - | - | - |
| Inventory | - | - | - | - | $8.64M | $5.23M | $4.65M | $4.09M | - | - |
| Current assets | $9.49M | $52.80M | $52.87M | $85.94M | $124.37M | $171.38M | $105.48M | $177.03M | $115.21M | $45.63M |
| Total assets | $9.49M | $55.48M | $55.95M | $86.82M | $139.43M | $221.61M | $154.32M | $220.97M | $116.55M | $46.33M |
| Current liabilities | $2.49M | $16.96M | $8.35M | $25.68M | $37.42M | $22.23M | $24.77M | $17.01M | $14.87M | $5.55M |
| Short-term debt | - | $10.34M | - | $5.00M | - | - | - | - | $6.67M | $556.0K |
| Long-term debt | - | $20.10M | $34.19M | $37.94M | $78.93M | $72.24M | $71.18M | $70.23M | $11.99M | $9.10M |
| Total debt | - | $30.44M | $34.19M | $42.94M | $78.93M | $72.24M | $71.18M | $70.23M | $18.65M | $9.65M |
| Total liabilities | $2.49M | $43.15M | $48.45M | $67.85M | $122.62M | $121.61M | $124.63M | $115.99M | $26.87M | $15.70M |
| Shareholders' equity | $7.00M | $12.33M | $7.50M | $18.97M | $16.80M | $100.00M | $29.69M | $104.98M | $89.68M | -$87.76M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.99M | -$29.38M | -$27.93M | -$78.91M | -$108.23M | -$90.69M | -$92.72M | -$54.12M | -$34.10M | -$27.35M |
| Capital expenditures | - | - | - | - | - | - | $1.33M | $1.58M | $480.0K | $153.0K |
| Free cash flow | - | - | - | - | - | - | -$94.06M | -$55.70M | -$34.58M | -$27.50M |
| Investing cash flow | -$15.0K | -$208.0K | -$429.0K | $62.72M | $70.80M | -$78.21M | -$1.33M | -$1.58M | -$480.0K | -$153.0K |
| Financing cash flow | -$11.62M | $29.88M | $8.51M | -$7.94M | $42.55M | $160.63M | $8.98M | $124.10M | $103.70M | $67.21M |
| Stock-based compensation | $7.00M | $8.39M | $7.46M | $7.01M | $16.09M | $13.31M | $9.99M | $8.62M | $3.57M | $2.07M |
| Depreciation and amortization | $317.0K | $259.0K | $303.0K | $537.0K | $975.0K | $912.0K | $843.0K | - | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | -100.0% | -65.4% | 76.7% | 4.7% | - | - | - | -100.0% |
| Operating margin | - | - | - | -2099.3% | -1158.8% | -1512.6% | -1452.5% | - | - | - |
| Net margin | - | - | - | -1151.6% | -1268.7% | -1639.8% | -1553.3% | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | -1548.5% | - | - | - |
| Return on equity | -385.6% | -312.3% | -562.4% | -236.2% | -848.6% | -104.3% | -317.8% | -63.6% | -47.1% | - |
| Return on assets | -284.3% | -69.4% | -75.4% | -51.6% | -102.3% | -47.1% | -61.1% | -30.2% | -36.2% | -71.6% |
| Current ratio | 3.81 | 3.11 | 6.33 | 3.35 | 3.32 | 7.71 | 4.26 | 10.41 | 7.75 | 8.23 |
| Debt to equity | - | 2.47 | 4.56 | 2.26 | 4.70 | 0.72 | 2.40 | 0.67 | 0.21 | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $59.0K | $61.0K | $366.0K | $6.13M | $6.23M | $6.05M | $5.26M | $5.17M | $5.32M | $6.35M | $4.72M | $5.55M |
| Selling, general and admin | $1.66M | $1.74M | $9.86M | $4.53M | $4.64M | $4.59M | $4.20M | $4.40M | $4.32M | $5.42M | $4.62M | $4.95M |
| Operating income | -$1.72M | -$1.80M | -$10.22M | -$7.24M | -$11.03M | -$10.67M | -$9.46M | -$9.99M | -$9.61M | -$11.93M | -$9.62M | -$8.76M |
| Interest expense | - | - | $141.0K | $963.0K | $1.08M | $1.09M | $1.39M | $1.48M | $1.46M | $1.46M | $1.47M | $1.46M |
| Net income | -$1.58M | -$1.62M | $686.0K | -$7.56M | -$11.15M | -$8.95M | -$8.18M | -$8.95M | -$9.58M | -$11.81M | -$8.63M | -$8.70M |
| EPS, basic | -$21.32 | -$0.14 | - | -$53.50 | -$85.64 | -$70.49 | - | -$96.50 | -$158.00 | -$210.00 | -$129.50 | -$170.50 |
| EPS, diluted | -$21.32 | -$0.14 | - | -$53.50 | -$85.64 | -$70.49 | - | -$96.50 | -$158.00 | -$210.00 | -$129.50 | -$170.50 |
| Diluted shares | 74,159 | 11.9M | - | 140,849.14 | 130,262 | 126,917 | - | 92,551.56 | 60,604.26 | 56,264.2 | - | 51,004.2 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $229.0K | $1.76M | $7.56M | $21.10M | $31.94M | $42.22M | $51.18M | $49.20M | $54.20M | $48.48M | $50.90M | $56.06M |
| Short-term investments | $7.00M | $7.00M | - | - | - | - | - | - | - | - | - | - |
| Current assets | $10.58M | $12.32M | $9.49M | $24.27M | $33.66M | $45.72M | $52.80M | $51.28M | $58.85M | $50.09M | $52.87M | $57.90M |
| Total assets | $10.58M | $12.32M | $9.49M | $25.02M | $36.05M | $48.25M | $55.48M | $54.08M | $61.61M | $53.03M | $55.95M | $61.12M |
| Current liabilities | $1.54M | $1.56M | $2.49M | $32.57M | $16.02M | $22.98M | $16.96M | $23.87M | $19.19M | $11.88M | $8.35M | $10.30M |
| Short-term debt | - | - | - | $28.41M | $9.51M | $15.50M | $10.34M | $17.98M | $11.98M | $5.99M | - | - |
| Long-term debt | - | - | - | - | $18.79M | $15.12M | $20.10M | $17.16M | $22.83M | $28.51M | $34.19M | $33.88M |
| Total debt | - | - | - | $26.95M | $28.30M | $30.62M | $30.44M | $35.14M | $34.82M | $34.50M | $34.19M | $33.88M |
| Total liabilities | $1.54M | $1.56M | $2.49M | $33.69M | $39.26M | $42.54M | $43.15M | $47.22M | $47.89M | $46.37M | $48.45M | $49.90M |
| Shareholders' equity | $9.04M | $10.76M | $7.00M | -$8.66M | -$3.21M | $5.71M | $12.33M | $6.86M | $13.72M | $6.66M | $7.50M | $11.22M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.53M | -$2.90M | -$4.56M | -$10.88M | -$16.56M | -$8.82M | -$4.60M | -$4.72M | -$9.21M | -$10.84M | -$7.70M | -$2.95M |
| Investing cash flow | $0 | -$7.00M | $0 | $1.0K | - | - | -$69.0K | -$90.0K | -$36.0K | -$13.0K | -$7.0K | $9.72M |
| Financing cash flow | $0 | $4.10M | -$8.98M | $30.0K | -$2.53M | -$135.0K | $6.65M | -$180.0K | $14.97M | $8.44M | $2.54M | $40.0K |
| Stock-based compensation | -$136.0K | -$471.0K | $401.0K | $2.04M | $2.24M | $2.31M | $2.09M | $2.04M | $1.88M | $2.38M | $2.37M | $2.40M |
| Depreciation and amortization | - | - | $54.0K | $128.0K | $67.0K | $68.0K | $69.0K | $63.0K | $61.0K | $66.0K | $70.0K | $79.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 6.88 | 7.91 | 3.81 | 0.75 | 2.10 | 1.99 | 3.11 | 2.15 | 3.07 | 4.22 | 6.33 | 5.62 |
| Debt to equity | - | - | - | - | - | 5.37 | 2.47 | 5.12 | 2.54 | 5.18 | 4.56 | 3.02 |
Source: XBRL data KALA BIO Inc. files with the SEC, latest filing dated Aug 19, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 2-for-99, first reported Mar 3, 2023; 1-for-50, first reported May 15, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
KALA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| KALA | $0 | - | -$26.98M | - | $3.4M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
KALA FAQ
6 questionsWhat is KALA revenue?
KALA BIO Inc. (KALA) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025).Is KALA profitable?
No. KALA BIO Inc. reported a net loss of $26.98M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does KALA have?
KALA BIO Inc. reported $229.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.What is KALA earnings per share?
Diluted earnings per share were -$165.50 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did KALA last report financial results?
The latest statements here come from KALA BIO Inc.'s 10-Q filed on Aug 19, 2026, covering the period ended Jun 30, 2026.Where does this KALA financial data come from?
Quantisnow builds these statements from the structured XBRL data KALA BIO Inc. files with the SEC. It is provided for information only and is not investment advice.